Literature DB >> 31291562

Venetoclax for Refractory Myeloid Sarcoma.

Abraham S Kanate1, Jeffrey Vos1, Michael J Chargualaf1.   

Abstract

Entities:  

Year:  2019        PMID： 31291562     DOI： 10.1200/JOP.18.00753

Source DB:  PubMed          Journal:  J Oncol Pract        ISSN： 1554-7477            Impact factor:   3.840


× No keyword cloud information.
  7 in total

Review 1.  Target Therapy for Extramedullary Relapse of FLT3-ITD Acute Myeloid Leukemia: Emerging Data from the Field.

Authors:  Andrea Duminuco; Cinzia Maugeri; Marina Parisi; Elisa Mauro; Paolo Fabio Fiumara; Valentina Randazzo; Domenico Salemi; Cecilia Agueli; Giuseppe Alberto Palumbo; Alessandra Santoro; Francesco Di Raimondo; Calogero Vetro
Journal:  Cancers (Basel)       Date:  2022-04-27       Impact factor: 6.575

2.  Long-term remission of extramedullary cutaneous relapse of acute myeloid leukaemia (leukaemia cutis) treated with decitabine-venetoclax.

Authors:  Denise Maravalle; Alessandra Filosa; Catia Bigazzi; Guido Collina; Piero Galieni
Journal:  EJHaem       Date:  2022-01-28

3.  Isolated Intracranial Myeloid Sarcoma Mimicking Malignant Lymphoma: A Diagnostic Challenge and Literature Reviews.

Authors:  Guixuan Xu; Haijun Zhang; Weixia Nong; Chunsen Li; Lian Meng; Chunxia Liu; Feng Li
Journal:  Onco Targets Ther       Date:  2020-06-25       Impact factor: 4.147

4.  The myeloid sarcoma treated by Venetoclax with hypomethylating agent followed by stem cell transplantation: rare case report.

Authors:  Aleksina Shatilova; Larisa Girshova; Daniil Zaytsev; Irina Budaeva; Yuliya Mirolyubova; Darya Ryzhkova; Roman Grozov; Konstantin Bogdanov; Tatiana Nikulina; Dmitriy Motorin; Darina Zammoeva; Svetlana Efremova; Vladimir Ivanov; Alexey Petukhov; Yuliya Alekseeva; Andrey Zaritskey
Journal:  BMC Womens Health       Date:  2021-05-01       Impact factor: 2.742

5.  Clinical characteristics, treatment, and prognosis of 118 cases of myeloid sarcoma.

Authors:  Haiqiu Zhao; Zhenkun Dong; Dingming Wan; Weijie Cao; Haizhou Xing; Zhenzhen Liu; Jixin Fan; Haiqiong Wang; Runqing Lu; Yinyin Zhang; Qianqian Cheng; Zhongxing Jiang; Fei He; Xinsheng Xie; Rong Guo
Journal:  Sci Rep       Date:  2022-04-26       Impact factor: 4.996

6.  Incidence, clinical characteristics, and prognostic nomograms for patients with myeloid sarcoma: A SEER-based study.

Authors:  Ziping Xing; Xiaohua Zhu; Zifeng Li; Hongsheng Wang; Maoxiang Qian; Xiaowen Zhai
Journal:  Front Oncol       Date:  2022-08-18       Impact factor: 5.738

Review 7.  Programmed cell death, redox imbalance, and cancer therapeutics.

Authors:  Xiaofeng Dai; Danjun Wang; Jianying Zhang
Journal:  Apoptosis       Date:  2021-07-08       Impact factor: 4.677
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.